Thrombomodulin accelerates activated protein C production and inhibits thrombin generation in the plasma of disseminated intravascular coagulation patients

Thrombomodulin (TM) has been under development as a medicine for disseminated intravascular coagulation (DIC), and is expected to exhibit strong anticoagulant activity by inhibiting thrombin generation via the acceleration of protein C activation. In the present study, we examined the pharmacological action of TM in plasma obtained from DIC patients. TM was found to inhibit thrombin generation and accelerate activated protein C (APC) production at 0.3–30 TM units/ml in plasma obtained from DIC patients irrespective of their underlying disorders. In addition, there was a positive correlation between the inhibition of thrombin generation and the amount of APC produced. Thrombin generation was inhibited by over 50% when the plasma level of APC was increased by more than 0.2 μg/ml. These results indicate that TM inhibits thrombin generation in plasma obtained from DIC patients by accelerating APC production. Moreover, the results imply that the thrombin generation test may be a good method to speculate the efficacy of TM on every patient before the administration of TM.

[1]  T. Iba,et al.  [Disseminated intravascular coagulation]. , 2003, Nihon rinsho. Japanese journal of clinical medicine.

[2]  F B Taylor,et al.  Towards Definition, Clinical and Laboratory Criteria, and a Scoring System for Disseminated Intravascular Coagulation , 2001, Thrombosis and Haemostasis.

[3]  Y. Ito,et al.  Structural analysis of the sugar chains of human urinary thrombomodulin. , 2001, Journal of biochemistry.

[4]  C. Esmon.  Regulation of blood coagulation. , 2000, Biochimica et biophysica acta.

[5]  E. Gabazza,et al.  Diagnosis of Disseminated Intravascular Coagulation by Hemostatic Molecular Markers , 2000, Seminars in thrombosis and hemostasis.

[6]  H. Niina,et al.  ATIII-independence of anticoagulant effect of human urinary soluble thrombomodulin. , 1999, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[7]  B. Blauhut.  Indications for prothrombin complex concentrates in massive transfusions. , 1999, Thrombosis research.

[8]  H. Altunbas,et al.  Circadian Variations in Natural Coagulation Inhibitors Protein C, Protein S and Antithrombin in Healthy Men: A Possible Association with Interleukin-6 , 1999, Thrombosis and Haemostasis.

[9]  E. Gabazza,et al.  Hemostatic molecular markers before the onset of disseminated intravascular coagulation , 1999, American journal of hematology.

[10]  N. Otsuki,et al.  Novel Proteoglycan Linkage Tetrasaccharides of Human Urinary Soluble Thrombomodulin, SO4-3GlcAβ1–3Galβ1–3(±Siaα2–6)Galβ1–4Xyl* , 1999, The Journal of Biological Chemistry.

[11]  G. Rodgers,et al.  Disseminated intravascular coagulation: Clinical and laboratory aspects , 1998, American journal of hematology.

[12]  H. Shiku,et al.  Poor outcome in disseminated intravascular coagulation or thrombotic thrombocytopenic purpura patients with severe vascular endothelial cell injuries , 1998, American journal of hematology.

[13]  H. Niina,et al.  Species specificity of the anticoagulant activity of human urinary soluble thrombomodulin. , 1998, Thrombosis research.

[14]  Y. Hosaka,et al.  Human Urinary Soluble Thrombomodulin (MR-33) Improves Disseminated Intravascular Coagulation without Affecting Bleeding Time in Rats: Comparison with Low Molecular Weight Heparin , 1997, Thrombosis and Haemostasis.

[15]  Andrew Tam,et al.  The Effects of Dermatan Sulfate at Submicrogram/ml Concentrations on In Vitro Thrombin Generation , 1996, Thrombosis and Haemostasis.

[16]  T. Baglin.  Fortnightly Review: Disseminated intravascular coagulation: diagnosis and treatment , 1996 .

[17]  T. Matsuda.  Clinical aspects of DIC--disseminated intravascular coagulation. , 1996, Polish journal of pharmacology.

[18]  H. Shiku,et al.  Outcome of Disseminated Intravascular Coagulation in Relation to the Score when Treatment was Begun , 1995, Thrombosis and Haemostasis.

[19]  Y. Hosaka,et al.  Soluble Thrombomodulin Purified from Human Urine Exhibits a Potent Anticoagulant Effect In Vitro and In Vivo , 1995, Thrombosis and Haemostasis.

[20]  H. Asakura,et al.  Study of the balance between coagulation and fibrinolysis in disseminated intravascular coagulation using molecular markers. , 1994, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[21]  S. Béguin,et al.  A New Assay Based on Thrombin Generation Inhibition to Detect Both Protein C and Protein S Deficiencies in Plasma , 1994, Thrombosis and Haemostasis.

[22]  H. Hemker.  Thrombin generation: An essential step in haemostasis and thrombosis , 1994 .

[23]  M. Nakagawa,et al.  Clinical evaluation of low-molecular-weight heparin (FR-860) on disseminated intravascular coagulation (DIC)--a multicenter co-operative double-blind trial in comparison with heparin. , 1993, Thrombosis research.

[24]  R. Kandrotas,et al.  Heparin Pharmacokinetics and Pharmacodynamics , 1992, Clinical pharmacokinetics.

[25]  Tatsuya Hayashi,et al.  Plasma thrombomodulin as a marker of vascular disorders in thrombotic thrombocytopenic purpura and disseminated intravascular coagulation , 1992, American journal of hematology.

[26]  H. Hemker,et al.  The Mode of Action of Heparin in Plasma , 1988, Thrombosis and Haemostasis.

[27]  T. Maekawa,et al.  Tissue factor activity in leukemia cells. Special reference to disseminated intravascular coagulation , 1987, Cancer.

[28]  C. Esmon.  Protein-C: biochemistry, physiology, and clinical implications. , 1983, Blood.

[29]  C. Esmon,et al.  Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C. , 1982, The Journal of biological chemistry.

[30]  R. Marlar,et al.  Mechanism of action of human activated protein C, a thrombin-dependent anticoagulant enzyme. , 1982, Blood.

[31]  J. Hirsh,et al.  A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. , 1972, The New England journal of medicine.